ArticleMolecular therapy. Nucleic acids2026
miRNA675-5p inhibitor's dual role as novel therapeutic alternative or sensitizing treatment in resistant glioma models.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting HypoxamiRs: A new perspective on overcoming treatment resistant glioblastoma.Molecular therapy. Nucleic acids · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is currently the most aggressive CNS tumor. MicroRNA (miRNA)675-5p is a hypoxic miRNA involved in promoting and maintaining the hypoxia inducible factor (HIF)-1α pathway, the driving force for glioma proliferation, migration into surrounding tissue, and resistance. Its inhibition is effective in reducing HIF-1α and all pathways related to it. However, the molecular mechanism through which miRNA inhibition is effective has not yet been fully elucidated. The therapeutic efficacy of the miRNA675-5p inhibitor was tested in a panel of resistant glioma lines evaluating the cellular, molecular, and biochemical rearrangement of the cells after treatment, with particular attention to the oxidative stress imbalance. miRNA675-5p inhibitor has a therapeutic efficacy on its own in resistant cell lines, reducing HIF-1α and its related pathways. The mechanism through which this occurs is the induction of oxidative stress. Its impairment, in fact, reverses the cytotoxic effect. Inhibitor-treated cells acquire metabolic characteristics clearly distinct from untreated cells, triggering compensatory mechanisms that must be considered for the secondary treatment of glioma with temozolomide. The induction of oxidative stress and metabolic rearrangement play key roles in the cytotoxic effect of the miRNA675-5p inhibitor, which could be proposed as a new therapeutic approach in glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.